Recent Advances in Chemotherapy for Advanced Gastric Cancer Toshihiko Doi 1 , Athushi Ohtsu 1 , Kiyomi Mera 1 , Manabu Muto 1 , Yasushi Sano 1 1Division of Gastrointestinal Oncology/Digestive Endoscopy, National Cancer Center Hospital East Keyword: chemotherapy , gastric cancer pp.89-94
Published Date 2003/1/25
DOI https://doi.org/10.11477/mf.1403101008
  • Abstract
  • Look Inside
  • Reference

 In Japan, the mortality rate of gastric cancer has been decreased by the spread of diagnosis and surgical treatment for early gastric and the decrease of gastric cancer frequency. Although chemotherapy for advanced gastric cancer contributes to survival benefit as compared to best supportive care based on randomized controlled studies, no standard regimens which are superior to 5-fluorouracil(5-FU)alone in survival benefit have been demonstrated yet. Recent progress of new anti-cancer drugs such as irinotecan(CPT-11)and S-1 have provided higher response rates than previous chemotherapeutic regimens. CPT-11 in combination with cisplatin or with mitomycin-C yielded a response rate of nearly 60 % for chemo-naive patients and S-1 also provided a response rate of 45 % in a single agent study and 76 % in combination study with cisplatin. Two randomized controlled trials(5-FU alone vs. CPT-11+CDDP vs. S-1 alone supported by Japan Clinical Oncology Group(JCOG)and S-1 vs. S-1+CDDP sponsored by a drug company)for patients with advanced gastric cancer has been held to clarify whether these new regimens improve survival outcomes.

Copyright © 2003, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1219 印刷版ISSN 0536-2180 医学書院